[ Price : $8.95]
FDA posts a seven-item Form FDA-483 after inspecting Dr. Reddys Mirfield, West Yorkshire, UK, active pharmaceutical ingredient man...[ Price : $8.95]
Intellia Therapeutics pauses two Phase 3 trials of nex-z, a CRISPR-based therapy for transthyretin amyloidosis with cardiomyopathy...[ Price : $8.95]
A Senate Committee demands answers from HHS on what they describe as serious national security and public health risks tied to Ame...[ Price : $8.95]
FDA sends Sydnexis a complete response letter for SYD-101, a low-dose atropine eye-drop candidate intended to slow disease progres...[ Price : $8.95]
FDA grants Partner Therapeutics a breakthrough therapy designation for zenocutuzumab-zbco and its use in treating cholangiocarcino...[ Price : $8.95]
Inhibrx Biosciences reports favorable data for treating chondrosarcoma with its antibody therapy ozekibart (INBRX-109).[ Price : $8.95]
FDA posts a two-item Form FDA-483 from an August inspection of Sumitomo Pharmas Suzuka, Japan, manufacturing facility.[ Price : $8.95]
An FDA payroll system error causes a paycheck delay for some FDA employees who are designated to continue working during the ongoi...